A novel treatment strategy for newly diagnosed high-grade T1 bladder cancer: Gemcitabine and cisplatin adjuvant chemotherapy—A single-institution experience

详细信息    查看全文

• 作者：Guo-liang Yang ; M.D.^a ; Lian-hua Zhang ; M.D.^a ; Qiang Liu ; M.D.^b ; Zhao-liang Wang ; M.D.^b ; Xue-hui Duan ; M.D.^a ; Yi-ran Huang ; M.D.^a ; Juan-jie Bo ; M.D.^a ; ^{bojuanjie@sina.com}
• 关键词：Bladder cancer ; Adjuvant chemotherapy ; Progression
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：35
• 期：2
• 页码：38.e9-38.e15
• 全文大小：436 K
• 卷排序：35

文摘

The first study to report that GC adjuvant chemotherapy is a safe conservative treatment for T1G3 bladder cancer. Patients with T1G3 tumor concomitant CIS should be treated more aggressively because of the high risk of progression. We are expecting a further validation in a larger population.